Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However, in cases of failure or adverse events related to these drugs, another TNFi such as certolizumab pegol (CZP) could be an effective option (1) as we have previously reported (2). Moreover, given that CZP does not cross the placental barrier (3), this drug could be a safer option in women considering pregnancy. Our purpose is to study the efficacy and safety of CZP in patients with uveitis refractory to other immunomodulatory treatments
Methods: Observational, multicentric, retrospective study. All the patients with a diagnosis of uveitis, confirmed by an Ophtalmologist, treated with CZP for at least 6 months were included. Variables analyzed: age, sex, diagnosis, type of uveitis and duration since the first uveitis episode; previous treatment (NSAID, disease-modifying anti-rheumatic drugs (DMARDs), immunossuppressive or biological therapy); outcome and time to follow-up
Conclusion: CZP has demonstrated effectiveness in patients with refractory uveitis to previous TNFi treatment, showing a safety profile that even allows its use in patients with pregnancy desire References: 1. Rudwaleit M et al Arthritis Care Res (Hoboken). 2016; 68: 838-44. 2. Llorenç V et al. Ocul Immunol Inflamm. 2016; 24: 167-72. 3. Porter C. J Reprod Immunol. 2016; 116: 7-12
To cite this abstract in AMA style:Hernández MV, Mesquida M, Llorens V, Sainz de la Maza M, Espinosa G, Blanco R, Calvo V, Maiz O, Blanco A, De Dios JR, Ahijado-Guzman P, Judez E, Tejón P, Peña MS, Sanmarti R, Adan A. Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/effectiveness-of-certolizumab-pegol-in-patients-with-uveitis-refractory-to-other-tumor-necrosis-factor-inhibitors-report-of-22-cases/. Accessed December 1, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/effectiveness-of-certolizumab-pegol-in-patients-with-uveitis-refractory-to-other-tumor-necrosis-factor-inhibitors-report-of-22-cases/